Fosun and BioNTech Explore Joint Developing Omicron-Specific Vaccine

Shanghai Fosun Pharmaceutical (Group) Co. Ltd. (600196.SH) said it will actively work with its German partner BioNTech SE to develop a new vaccine targeting the omicron variant of Covid-19, and it may take three to four months to win regulatory approval.

Fosun is the exclusive partner of BioNTech for marketing the mRNA vaccine co-developed by BioNTech and U.S. drug giant Pfizer Inc. in Greater China, including Hong Kong, Macao and Taiwan. Known in China as the Comirnaty vaccine, the product hasn’t been approved for the Chinese mainland.